GlassScriptPhysician profile
Allison Mccharen
NPI 1720673726
$9,222.49
in general payments reported to CMS, 2019-2025
30 companies · $2,468 in 2025
The $2,468 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $2,324 · 2023: $2,321 · 2024: $1,900 · 2025: $2,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,576 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,576.23 |
| Education | $112.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,222.61 | 2021-2025 | |
| Incyte Corporation | $830.94 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $672.08 | 2023-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $520.54 | 2022-2025 | Sotyktu |
| Amgen INC. | $485.26 | 2022-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $436.10 | 2022-2025 | Ilumya, Blu-U, Odomzo |
| Genzyme Corporation | $399.57 | 2021-2025 | |
| Janssen Biotech, INC. | $384.43 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $381.71 | 2022-2024 | |
| Ucb, INC. | $381.21 | 2022-2025 | Bimzelx, Cimzia |
| Medimetriks Pharmaceuticals, INC. | $371.08 | 2022-2023 | Neo-Synalar |
| Regeneron Healthcare Solutions, INC. | $356.01 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $266.49 | 2023-2025 | Taltz, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $255.42 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Galderma Laboratories, L.P. | $230.61 | 2022-2025 | Nemluvio, Aklief |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $175.26 | 2023-2025 | |
| Almirall LLC | $131.85 | 2022-2024 | Klisyri, Seysara |
| Dermavant Sciences, INC. | $124.40 | 2022-2024 | Vtama |
| Organon LLC | $111.28 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $93.34 | 2024-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.10 | 2023-2025 | Spevigo, Cyltezo |
| Sanofi-Aventis U.S. LLC | $69.99 | 2023 | |
| Organogenesis INC. | $46.20 | 2025 | Novachor, Affinity |
| Mayne Pharma Commercial LLC | $44.85 | 2022-2023 | |
| Journey Medical Corporation | $44.30 | 2022-2023 | |
| Botanix Sb INC | $31.61 | 2025 | Sofdra |
| Sandoz INC. | $23.47 | 2025 | Hyrimoz |
| Mallinckrodt Hospital Products INC. | $20.48 | 2025 | Acthar |
| Nabriva Therapeutics, Plc | $15.04 | 2022 | |
| Biofrontera INC. | $10.26 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Mccharen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.